The aura of therapeutic nihilism that embraced the diagnosis of HIV seropositivity in symptom-free individuals at the beginning of the 1990s has largely been dispersed, so that official advice is that on balance it is better to know than not to knowl2. Nowhere is this more true than in the sphere of maternity care. In addition to the basic benefits to the woman herself, there is the important issue of mother-tochild transmission3. Not only has a serious and usually lethal infection of infants and children been recognized, but also we have now learned that transmission of this disorder from mother to child can largely be prevented by measures taken during late pregnancy, during labour and in the early neonatal period. These include prophylactic anti-retroviral therapy given to the mother4, avoidance of breastfeeding5 and caesarean section6.
If we wish to achieve a substantial reduction in HIV transmission from mother to child, a fundamental requirement is to know the sero-status of the mother in time for appropriate interventions. This requirement has provoked a maelstrom of ethical, legal, special-interest, professional and economic arguments in an area already made tempestuous by issues of confidentiality, insurance loading, discrimination and minority rights, together with the move towards 'demedicalization'7.
AIDS IN EUROPE
The HIV infection epidemic in Europe has shown striking geographic variations both between and within individual states. Where intravenous drug use has overtaken male homosexual practice as a route for transmission, the impact of the disease on women has been immediate-even though the numbers remain small compared with the total affected male population. In such areas data began to emerge on vertical transmission of the infection from mother to child8.
The European Collaborative Study9'10 has contributed greatly to the pool of knowledge on this topic and has pointed to important differences, both across the Atlantic and between Europe and sub-Saharan Africa, in the natural history of heterosexually acquired HIV infection. Initially, 'at risk' groups were relatively easy to categorize but, with the involvement of seemingly low-risk heterosexuals and the concept of 'risk behaviour' rather than risk grouping, a public health need for HIV screening became apparent on both sides of the Atlantic11'12. At first the impetus was entirely epidemiological and for the public health, because at that time there was no direct benefit to the individual from the knowledge of HIV seropositive status. Early pregnancy was, however, always a notable exception in that a decision on whether to continue with the pregnancy could hinge on the result. Research data seemed to indicate that the uptake of this option was steady but low10' 3*
The need for epidemiological information has largely been answered by anonymized blood screening pro-grammes14; but as the balance of personal benefit has swung in favour of knowing HIV seropositive status, especially and outstandingly in pregnancy, the need for named (attributable) testing has become apparent. This is a change that has been denied or ignored at a personal or administrative level in many areas15 '16 In 1995 an ad hoc group of individuals from seven participating European Community countries was formed to collect and collate data on antenatal HIV testing in the European Community.
METHOD
Data on policies and procedures of HIV testing in pregnancy were collected from 15 member countries of the European Community during 1996 and 1997. These data were collected by means of a standardized checklist to monitor information on the number of AIDS cases by gender, AIDS cases population ratio, antenatal HIV seroprevalence, official policy on HIV testing in pregnancy and consent, approach to testing in practice and provision ofcounselling. Data Switzerland) or those from which information was not forthcoming.
The total AIDS cases in each country were derived from the European Non-Aggregate AIDS Data Set (June 1997). The AIDS cases population ratio was calculated according to the latest UN estimates of the respective countries17. Data on HIV seropositivity in the antenatal population and official policy and procedures on antenatal HIV testing were derived either from the collaborators or from the relevant health departments. For the UK, the antenatal seroprevalence data were derived from the national unlinked seroprevalence study14. The figures are generally valid for 1996 but the limitations on the quality and comparability of the data must be appreciated. 
RESULTS
The AIDS cases total in a population per 100000 ranged from 5 in Finland to 1 19 in Spain, showing large variation in how the HIV/AIDS epidemic has affected different member states (Table 1) . Female AIDS cases represented between 10% and 23% of the total AIDS cases reported. The estimated percentage of the antenatal population who are HIV positive is given where such figures are available.
Several countries have a selective policy of offering voluntary named HIV testing. Others have a variant of universal testing (see above). Germany, France and Sweden report a high uptake of testing, the UK much lower. In some areas the policy has changed, moving away from universal testing towards selective testing. An example is the Netherlands, where HIV seropositivity is believed to be concentrated in readily identifiable high-risk groups.
The provision and degree of pre-test counselling also show considerable variation both between and within countries. In some countries there is virtually no pre-test or post-test counselling or the extent and content is not specified. Furthermore, the distinction is blurred between formal 'counselling' and the provision by the professional (midwife or doctor) of sufficient information for informed consent to be obtained. The policy and practice for gathering women's consent for an HIV test are highly varied, and some European collaborators suggested that practice may not always correspond to official policy. DISCUSSION These data highlight several features that have not been widely appreciated. There is considerable variation over attitudes to 'consent' for investigation and the 'degree of encouragement' that is applied to achieve participation in a testing programme. Universal policies vary from mandatory (or near-mandatory) to routine-but-voluntary ('opt out') and voluntary with explicit consent ('opt in'), while in some places there is selective testing or even no test policy at all. Much of the female HIV seropositivity in Europe is related to intravenous drug use (either personal or through a drug-using heterosexual partner) and the local prevalence, as reported elsewhere by the European Collaborative Study, reflects the geographic vagaries of the drug-using cohorts, compounded by local habits of needle sharing (as exemplified by the experience in two Scottish centres). More recently the effect of immigration from countries where HIV is highly prevalent (chiefly sub-Saharan Africa) has become increasingly prominent. In London and some other capital cities this is now the major source of female HIV seropositivity18, 19.
These differences have had an obvious impact upon policy structure for HIV testing without a corresponding change in efficacy and acceptance and hence in detection rate. There has been a tendency to move towards a variant of universal testing. Selective testing has been deemed more cost-effective in areas of low seroprevalence and is relatively efficacious when a clinical history of risk factors (e.g. of intravenous drug use) is clear-cut20. With the advent of second-generation spread and of a high incidence of infection acquired abroad, cultural considerations, fear of discrimination and inherent methodological weaknesses2l'22 have seriously reduced the value of this method. Universal testing has, however, been adopted in certain low-risk communities and has proved efficacious especially where the test has been 'normalized' with other antenatal tests23. In some areas a degree of compulsion has been applied which would not be generally acceptable. Where, however, a totally laissez-faire attitude has been adopted, as in parts of the UK especially Greater London24'25, the acceptance rate has been so low as to render the programme scarcely worthwhile, leaving a legacy of HIV-infected children which could largely have been avoided3.
The ethics of this situation are very complex. We have reached a position where we might reasonably declare that every pregnant woman should have the right to an HIV test. Women also should have the right to full information when deciding on interventions that may be of benefit to their babies as well as to themselves. It remains true, however, that the critical information comes from a blood test; and this information can be acquired without 'further invasion' from a sample already taken for standard and acceptable purposes (e.g. rhesus antibody testing). Although in most legal systems a woman can refuse interventions (such as caesarean section) which have been planned in the interests of her unborn child rather than herself, it is a much more difficult ethical question, which society alone can solve, whether a woman should have the right 'not to know' some vital information concerning the wellbeing of her unborn child when this information can be obtained without further personal invasion. This dilemma becomes even more acute after the child is born, when its right to receive optimum care as an independent individual is no longer subordinate to that of its mother; the difficulty being that an HIV test carried out on the neonate is inevitably a vicarious test of its mother. Within the European Community the wide discrepancies between the policies and availability of antenatal HIV testing and in the efficacy of the programmes for the prevention of mother-to child vertical transmission serve only to highlight the dilemma with which the western world must come to terms. In many of the developing countries, of course, interventions useful for the prevention of vertical transmission are simply not available and the risks of avoiding breastfeeding outweigh the benefits. Society's views will in the end be moulded by those of women who wish to do the very best they can for their babies.
